Nanotechnology in Urology

Urologic Clinics of North America

Volumn 36, Issue 2, 2009, Pages 179-188

  Jin, Shihua ^a   Labhasetwar, Vinod ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Anticancer drugs; Cancer; Drug delivery; Imaging; Nanoparticles

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CREMOPHOR; DENDRIMER; DOXORUBICIN; IRINOTECAN; LIPOSOME; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY J591; MONOCRYSTALLINE IRON OXIDE NANOPARTICLE; NANOCARRIER; NANOPARTICLE; NANOSHELL; NK 012; OLEIC ACID; PACLITAXEL; PHOTOSENSITIZING AGENT; POLYETHERURETHAN; POLYGLACTIN; PROSTAGLANDIN E1; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TETRASULFOPHTHALOCYANINE ALUMINUM; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS VECTOR; DRUG CARRIER; NANOMATERIAL;

BACTERIUM DETECTION; BLADDER CANCER; BLADDER TUMOR; CANCER DIAGNOSIS; CANCER RESISTANCE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIALYSIS MEMBRANE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; EARLY DIAGNOSIS; ERECTILE DYSFUNCTION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; HEMODIALYSIS; HERPES SIMPLEX VIRUS; HUMAN; KIDNEY CARCINOMA; LIPOSOMAL DELIVERY; LIPOSOMAL GENE DELIVERY SYSTEM; LUNG METASTASIS; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NANOMEDICINE; NANOSENSOR; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOGENIC IMPOTENCE; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; TISSUE ENGINEERING; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CANCER; UROGENITAL TRACT DISEASE; UROLOGY; VIRAL GENE DELIVERY SYSTEM; GENETICS; URINARY TRACT DISEASE;

DIAGNOSTIC IMAGING; DRUG CARRIERS; HUMANS; NANOMEDICINE; NANOSTRUCTURES; POLYMORPHISM, SINGLE NUCLEOTIDE; UROLOGIC DISEASES;

EID: 65249158493     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2009.02.005     Document Type: Review

References (58)

1. Asiyanbola B., and Soboyejo W. For the surgeon: an introduction to nanotechnology. J Surg Educ 65 2 (2008) 155-161
2. Shergill I.S., Rao A., Arya M., et al. Nanotechnology: potential applications in urology. BJU Int 97 2 (2006) 219-220
3. Alexis F., Rhee J.W., Richie J.P., et al. New frontiers in nanotechnology for cancer treatment. Urol Oncol 26 1 (2008) 74-85
4. Wang X., Yang L., Chen Z.G., et al. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin 58 2 (2008) 97-110
5. Sun C., Lee J.S., and Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 60 11 (2008) 1252-1265
6. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 25 (2003) 2491-2499
7. Wunderbaldinger P., Josephson L., Bremer C., et al. Detection of lymph node metastases by contrast-enhanced MRI in an experimental model. Magn Reson Med 47 2 (2002) 292-297
8. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 2 (2008) 71-96
9. Guimaraes A.R., Tabatabei S., Dahl D., et al. Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer. Urology 71 4 (2008) 708-712
10. Manyak M.J., Javitt M., Kang P.S., et al. The evolution of imaging in advanced prostate cancer. Urol Clin North Am 33 2 (2006) 133-146 v
11. Harisinghani M.G., Saksena M., Ross R.W., et al. A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology 66 5 (2005) 1066-1071
12. Jain T.K., Morales M.A., Sahoo S.K., et al. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharmaceutics 2 3 (2005) 194-205
13. Jain T.K., Reddy M.K., Morales M.A., et al. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharmaceutics 5 2 (2008) 316-327
14. Jain T.K., Richey J., Strand M., et al. Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials 29 29 (2008) 4012-4021
15. Chan W.C., and Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 281 5385 (1998) 2016-2018
16. Shi C., Zhu Y., Cerwinka W.H., et al. Quantum dots: emerging applications in urologic oncology. Urol Oncol 26 1 (2008) 86-92
17. Smith A.M., Ruan G., Rhyner M.N., et al. Engineering luminescent quantum dots for in vivo molecular and cellular imaging. Ann Biomed Eng 34 1 (2006) 3-14
18. Gao X., Cui Y., Levenson R.M., et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22 8 (2004) 969-976
19. Bao Y.P., Huber M., Wei T.F., et al. SNP identification in unamplified human genomic DNA with gold nanoparticle probes. Nucleic Acids Res 33 2 (2005) e15
20. Qin W.J., and Yung L.Y. Nanoparticle-based detection and quantification of DNA with single nucleotide polymorphism (SNP) discrimination selectivity. Nucleic Acids Res 35 17 (2007) e111
21. Storhoff J.J., Marla S.S., Bao P., et al. Gold nanoparticle-based detection of genomic DNA targets on microarrays using a novel optical detection system. Biosens Bioelectron 19 8 (2004) 875-883
22. Zhou X., and Zhou J. Improving the signal sensitivity and photostability of DNA hybridizations on microarrays by using dye-doped core-shell silica nanoparticles. (Wash) Anal Chem 76 18 (2004) 5302-5312
23. Hateboer N., Veldhuisen B., Peters D., et al. Location of mutations within the PKD2 gene influences clinical outcome. Kidney Int 57 4 (2000) 1444-1451
24. Kozlowski P., Bissler J., Pei Y., et al. Analysis of PKD1 for genomic deletion by multiplex ligation-dependent probe assay: absence of hot spots. Genomics 91 2 (2008) 203-208
25. Son A., Dhirapong A., Dosev D.K., et al. Rapid and quantitative DNA analysis of genetic mutations for polycystic kidney disease (PKD) using magnetic/luminescent nanoparticles. Anal Bioanal Chem 390 7 (2008) 1829-1835
26. Basu M., Seggerson S., Henshaw J., et al. Nano-biosensor development for bacterial detection during human kidney infection: use of glycoconjugate-specific antibody-bound gold NanoWire arrays (GNWA). Glycoconj J 21 8-9 (2004) 487-496
27. Peer D., Karp J.M., Hong S., et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2 12 (2007) 751-760
28. Sahoo S.K., Ma W., and Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 112 2 (2004) 335-340
29. Sahoo S.K., and Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharmaceutics 2 5 (2005) 373-383
30. Sumitomo M., Koizumi F., Asano T., et al. Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression. Cancer Res 68 6 (2008) 1631-1635
31. Lu Z., Yeh T.K., Tsai M., et al. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res 10 22 (2004) 7677-7684
32. Derycke A.S., Kamuhabwa A., Gijsens A., et al. Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells. J Natl Cancer Inst 96 21 (2004) 1620-1630
33. Kiyokawa H., Igawa Y., Muraishi O., et al. Distribution of doxorubicin in the bladder wall and regional lymph nodes after bladder submucosal injection of liposomal doxorubicin in the dog. J Urol 161 2 (1999) 665-667
34. McNealy T.L., Trojan L., Knoll T., et al. Micelle delivery of doxorubicin increases cytotoxicity to prostate carcinoma cells. Urol Res 32 4 (2004) 255-260
35. Thangapazham R.L., Puri A., Tele S., et al. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol 32 5 (2008) 1119-1123
36. Cheng J., Teply B.A., Sherifi I., et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28 5 (2007) 869-876
37. Gu F., Zhang L., Teply B.A., et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A 105 7 (2008) 2586-2591
38. Patri A.K., Myc A., Beals Jr. J., et al. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 15 6 (2004) 1174-1181
39. Kawai N., Ito A., Nakahara Y., et al. Anticancer effect of hyperthermia on prostate cancer mediated by magnetite cationic liposomes and immune-response induction in transplanted syngeneic rats. Prostate 64 4 (2005) 373-381
40. Kawai N., Futakuchi M., Yoshida T., et al. Effect of heat therapy using magnetic nanoparticles conjugated with cationic liposomes on prostate tumor in bone. Prostate 68 7 (2008) 784-792
41. Stern J.M., Stanfield J., Lotany Y., et al. Efficacy of laser-activated gold nanoshells in ablating prostate cancer cells in vitro. J Endourol 21 (2007) 939-943
42. Stern J.M., Stanfield J., Kabbani W., et al. Selective prostate cancer thermal ablation with laser activated gold nanoshells. J Urol 179 2 (2008) 748-753
43. Winquist E., Ernst D.S., Jonker D., et al. Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract. Eur J Cancer 39 13 (2003) 1866-1871
44. Flaherty K.T., Malkowicz S.B., and Vaughn D.J. Phase I study of weekly liposome-encapsulated doxorubicin in patients with advanced, androgen-independent prostate cancer. Am J Clin Oncol 27 2 (2004) 136-139
45. Heidenreich A., Sommer F., Ohlmann C.H., et al. Prospective randomized phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma. Cancer 101 5 (2004) 948-956
46. Tyagi P., Chancellor M., Yoshimura N., et al. Activity of different phospholipids in attenuating hyperactivity in bladder irritation. BJU Int 101 5 (2008) 627-632
47. Engelhardt P.F., Plas E., Hubner W.A., et al. Comparison of intraurethral liposomal and intracavernosal prostaglandin-E1 in the management of erectile dysfunction. Br J Urol 81 3 (1998) 441-444
48. Foldvari M., Oguejiofor C., Afridi S., et al. Liposome encapsulated prostaglandin E1 in erectile dysfunction: correlation between in vitro delivery through foreskin and efficacy in patients. Urology 52 5 (1998) 838-843
49. Binder J., Braeutigam R., Oertl A., et al. Methylprednisolone in bilayer liposomes prolongs cardiac and renal allograft survival, inhibits macrophage activation, and selectively modifies antigen presentation and T-helper cell function in rat recipients. Transplant Proc 30 4 (1998) 1051
50. Verma I.M., and Somia N. Gene therapy: promises, problems and prospects. Nature 389 6648 (1997) 239-242
51. Roy I., Stachowiak M.K., and Bergey E.J. Nonviral gene transfection nanoparticles: function and applications in the brain. Nanomedicine 4 2 (2008) 89-97
52. Mastrobattista E., van der Aa M.A., Hennink W.E., et al. Artificial viruses: a nanotechnological approach to gene delivery. Nat Rev Drug Discov 5 2 (2006) 115-121
53. Prabha S., and Labhasetwar V. Critical determinants in PLGA/PLA nanoparticle-mediated gene expression. Pharm Res 21 2 (2004) 354-364
54. Larchian W.A., Horiguchi Y., Nair S.K., et al. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. Clin Cancer Res 6 7 (2000) 2913-2920
55. Hattori Y., and Maitani Y. Folate-linked lipid-based nanoparticle for targeted gene delivery. Curr Drug Deliv 2 3 (2005) 243-252
56. Nissenson A.R., Ronco C., Pergamit G., et al. Continuously functioning artificial nephron system: the promise of nanotechnology. Hemodial Int 9 3 (2005) 210-217
57. Pattison M., Webster T.J., Leslie J., et al. Evaluating the in vitro and in vivo efficacy of nano-structured polymers for bladder tissue replacement applications. Macromol Biosci 7 5 (2007) 690-700
58. Pattison M.A., Wurster S., Webster T.J., et al. Three-dimensional, nano-structured PLGA scaffolds for bladder tissue replacement applications. Biomaterials 26 15 (2005) 2491-2500